ResMed Inc. (ASX:RMD)

Australia flag Australia · Delayed Price · Currency is AUD
37.51
-0.90 (-2.34%)
At close: Dec 9, 2025
0.83%
Market Cap55.05B
Revenue (ttm)7.95B
Net Income (ttm)2.17B
Shares Outn/a
EPS (ttm)14.77
PE Ratio25.32
Forward PE22.36
Dividend0.34 (0.90%)
Ex-Dividend DateNov 12, 2025
Volume911,278
Average Volume1,181,520
Open37.80
Previous Close38.41
Day's Range37.51 - 37.88
52-Week Range32.04 - 45.25
Beta0.87
RSI41.27
Earnings DateJan 22, 2026

About ResMed

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally. The company operates in two segments, Sleep and Breathing Health, and Residential Care Software. It offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring... [Read more]

Sector Healthcare
Founded 1989
Employees 10,600
Stock Exchange Australian Securities Exchange
Ticker Symbol RMD
Full Company Profile

Financial Performance

In 2025, ResMed's revenue was $5.15 billion, an increase of 9.84% compared to the previous year's $4.69 billion. Earnings were $1.40 billion, an increase of 37.20%.

Financial numbers in USD Financial Statements

News

RMD Stock Set to Gain From FDA Clearance of AI-Enabled Smart Comfort

Resmed gains FDA's nod for Smart Comfort, an AI-driven CPAP tool boosting sleep therapy personalization and adherence.

4 hours ago - Nasdaq

Top 50 High-Quality Dividend Growth Stocks For December 2025

I track a custom universe of 50 high-quality dividend growth stocks to identify timely, attractive investment opportunities based on valuation and forward return potential. 28 of these stocks currentl...

14 hours ago - Seeking Alpha

Resmed Gets FDA Clearance For Personalized Therapy Comfort Settings; To Be Marketed As Smart Comfort

(RTTNews) - Resmed (RMD, RMD.AX), Monday announced it has received U.S. Food and Drug Administration (FDA) clearance for Personalized Therapy Comfort Settings (PTCS), to be marketed as Smart Comfort.

1 day ago - Nasdaq

Resmed (RMD) Achieves FDA Clearance for Smart Comfort Device

Resmed (RMD) Achieves FDA Clearance for Smart Comfort Device

1 day ago - GuruFocus

Resmed Receives FDA Clearance for Personalized Therapy Comfort Settings, to be Marketed as Smart Comfort, an AI-Enabled, Digital Medical Device That Helps Personalize CPAP Therapy

SAN DIEGO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced it has rece...

1 day ago - GlobeNewsWire

Healthcare & Biotech Stocks Rally After Hours: Sensei, Praxis, Cooper, Vanda, Cue, ResMed

(RTTNews) - Several healthcare and biotech names posted notable gains in Thursday's after-hours session, driven by clinical updates, earnings results, and regulatory developments.

4 days ago - Nasdaq

Insider Sell: Peter Farrell Sells 2,000 Shares of ResMed Inc (RMD)

Insider Sell: Peter Farrell Sells 2,000 Shares of ResMed Inc (RMD)

4 days ago - GuruFocus

Should You Continue to Hold RMD Stock in Your Portfolio?

Resmed sees strong mask sales, strategic acquisitions and international expansion despite macro and competitive challenges.

6 days ago - Nasdaq

Insider Sell Alert: Brett Sandercock Sells Shares of ResMed Inc (RMD)

Insider Sell Alert: Brett Sandercock Sells Shares of ResMed Inc (RMD)

6 days ago - GuruFocus

ResMed (RMD) Dropped from Goldman Sachs' APAC Conviction List

ResMed (RMD) Dropped from Goldman Sachs' APAC Conviction List

8 days ago - GuruFocus

PETER FARRELL At ResMed Acquires Stock Options Worth $7K

A substantial insider move unfolded on November 26, as FARRELL, Board Member at ResMed (NYSE: RMD), reported the acquisition of stock options for 1,331 shares in an SEC filing. What Happened: Disclos...

12 days ago - Benzinga

Michael J Farrell Makes Strategic Play: Invests $179K In ResMed Stock Options

Michael J Farrell , Chairman and CEO at ResMed (NYSE: RMD), reported acquisition of company stock options on November 26, according to a new SEC filing. What Happened: Revealed in a Form 4 filing on ...

12 days ago - Benzinga

Insider Sell: Witte De Sells 2,055 Shares of ResMed Inc (RMD)

Insider Sell: Witte De Sells 2,055 Shares of ResMed Inc (RMD)

12 days ago - GuruFocus

IDEXX Laboratories Vs ResMed: Which Stock Could Rally?

IDEXX Laboratories' (IDXX) recent jump has investors questioning whether it's still the best bet—or if a stronger opportunity exists elsewhere. A closer look at its key competitor suggests there may b...

14 days ago - Forbes

ResMed Inc. (RMD) Announces Key Amendments to Incentive and Stock Purchase Plans

ResMed Inc. (RMD) Announces Key Amendments to Incentive and Stock Purchase Plans

18 days ago - GuruFocus

Peter C Farrell Exercises Options, Realizes $1.65M

A substantial insider activity was disclosed on November 18, as Farrell, Board Member at ResMed (NYSE: RMD), reported the exercise of a large sell of company stock options. What Happened: A Form 4 fi...

20 days ago - Benzinga

Noteworthy Tuesday Option Activity: AAPL, NVDA, RMD

Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in Apple Inc (Symbol: AAPL), where a total of 396,023 contracts have traded so far, representing ap...

20 days ago - Nasdaq

Could GLP-1 Drugs Make ResMed's CPAP Machines Obsolete?

ResMed faces an uncertain future as GLP-1 weight loss drugs threaten to reduce demand for sleep apnea devices, creating a complex investment dilemma for shareholders of the CPAP machine leader.

26 days ago - The Motley Fool

Ex-Dividend Reminder: UNITIL, American Water Works and ResMed

Looking at the universe of stocks we cover at Dividend Channel, on 11/13/25, UNITIL Corp (Symbol: UTL), American Water Works Co, Inc. (Symbol: AWK), and ResMed Inc. (Symbol: RMD) will all trade ex-div...

4 weeks ago - Nasdaq

RMD: Baird Lowers Price Target for ResMed to $300 While Maintaining Outperform Rating | RMD ...

RMD: Baird Lowers Price Target for ResMed to $300 While Maintaining Outperform Rating | RMD Stock News

5 weeks ago - GuruFocus

RMD: RBC Capital Raises Price Target, Maintains Outperform Rating | RMD Stock News

RMD: RBC Capital Raises Price Target, Maintains Outperform Rating | RMD Stock News

5 weeks ago - GuruFocus

Keybanc Analyst Raises ResMed (RMD) Price Target to $299 | RMD Stock News

Keybanc Analyst Raises ResMed (RMD) Price Target to $299 | RMD Stock News

5 weeks ago - GuruFocus

Mizuho Maintains 'Outperform' for RMD but Lowers Price Target | RMD Stock News

Mizuho Maintains 'Outperform' for RMD but Lowers Price Target | RMD Stock News

5 weeks ago - GuruFocus

These Analysts Revise Their Forecasts On ResMed Following Q1 Results

ResMed Inc. (NYSE:RMD) reported better-than-expected earnings for the first quarter on Thursday.

5 weeks ago - Benzinga